Surgery versus implant for early prostate cancer: Results from a single institution, 1992-2005

Cancer Journal

Volumn 13, Issue 4, 2007, Pages 229-232

  Colberg, John W ^a   Decker, Roy H ^a   Khan, Anwar M ^a   McKeon, Ann ^a   Wilson, Lynn D ^a   Peschel, Richard E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Implant; Prostate cancer; Surgery

Indexed keywords

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; PALLADIUM; RADIOACTIVE IODINE; RADIOISOTOPE;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSIMETRY; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; ULTRASOUND GUIDED TRANSPERINEAL IMPLANT; BLOOD; BRACHYTHERAPY; COMPARATIVE STUDY; MIDDLE AGED; PROSTATE TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOISOTOPES; TREATMENT OUTCOME;

EID: 35748962349     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318046f14e     Document Type: Article

References (31)

1. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166:416-419.
2. Potters L. Permanent prostate brachytherapy: lessons learned, lessons to learn. Oncology. 2000;14:981-991.
3. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol. 2003;4:233-241.
4. Ramos CG, Carvahal GF, Smith DS, et al. Retrospective comparison of radical retropubic prostatectomy and iodine-125 brachytherapy for localized prostate cancer. J Urol. 1999;161:1212-1215.
5. King CR, Sanzone J, Anderson KR, et al. Definitive therapy for stage T1/T2 prostate carcinoma: PSA-based comparison between surgery, external beam, and implant therapy. J Brachyther Int. 1998;14:169-177.
6. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
7. Keyser D, Kupelian PA, Zippe CD, et al. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery? Int J Radiat Oncol Biol Phys. 1997;38: 723-729.
8. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103-106.
9. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821-827.
10. Prostate. In: Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook, 6th ed. New York, NY: Springer-Verlag, 2002:337-345.
11. Lepor H, Guerna M. Surgical management of prostate cancer. In: Ernstoff MS, Heaney JA, Peschel RE, eds. Prostate Cancer. Oxford, England: Blackwell Science, 1998:91-106.
12. Peschel RE, Chen Z, Roberts K, et al. Long-term complications with prostate implants: iodine-125 vs. palladium-103. Radiat Oncol Invest. 1999;7:278-288.
13. Blasko JC, Grimm PD, Ragde H, et al. In: Ernstoff MS, Heaney JA, Peschel RE, eds. Prostate Cancer. Oxford, England: Blackwell Science, 1998:137-155.
14. Nath R, Roberts K, Ng M, et al. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants. Med Phys. 1998;25:2293-2307.
15. Yue N, Chen Z, Peschel RE, et al. Optimum timing for image-based dose evaluation of 125I and 103Pd prostate seed implants. Int J Radiat Oncol Biol Phys. 1999;45:1063-1078.
16. Peschel RE, Khan A, Colberg J, et al. The effect of age on prostate implantation results. Cancer J. 2006;12:305-308.
17. Potters L, Cha C, Oshinsky G, et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachy-therapy. Cancer JSci Am. 1999;5:301-306.
18. Blasko JC, Grimm PD, Sylvester JE, et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol. 2000;57:273-278.
19. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167: 528-534.
20. King CR, Long JP. Prostate biopsy grading errors: a sampling problem? Int J Cancer. 2000;90:326-330.
21. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chron Dis. 1958;8:699-712.
22. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:1487-1493.
23. Kupelian P, Katcher J, Levin H, et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am. 1997;3:78-87.
24. Powell IJ, Dey J, Dudley A, et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology. 2002;59:907-912.
25. Anai S, Pendleton J, Wludyka P, et al. Prostate cancer screening and detection in inner-city and underserved men. J Natl Med Assoc. 2006; 98:515-519.
26. Latini DM, Elkin EP, Cooperberg MR, et al. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006;106:789-795.
27. Cohen JH, Schoenbach VJ, Kaufman JS, et al. Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control. 2006; 17:803-811.
28. Makridakis NM, Ross RK, Pike MC, et al. Association of a mis-sense mutation in the SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet. 1999;354:975-978.
29. Merrick GS, Butler WM, Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:32-43.
30. Le CQ, Gettman MT. Laparoscopic and robotic radical prostatectomy. Expert Rev Anticancer Ther. 2006;6:1003-1011.
31. Peschel RE, Colberg JW, Chen Z, et al. Iodine-125 versus palladium103 implants for prostate cancer: clinical outcomes and complications. Cancer J. 2004;10:170-174.